Development of systemic lupus erythematosus with focal proliferative lupus nephritis during anti-TNF-α therapy for psoriatic arthritis;Entwicklung eines systemischen lupus erythematodes mit fokaler proliferativer lupusnephritis unter einer anti-TNF-α-therapie bei psoriasisarthritis

Medizinische Klinik

Volumn 102, Issue 10, 2007, Pages 852-857

  Haake, Hendrik ^a   Köneke, Jens ^a   Amann, Kerstin ^b   Vom Dahl, Jürgen ^a   Janssen, Ulf ^a  

^a KLINIKEN MARIA HILF GMBH   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Anti TNF therapy; Etanercept; Lupus nephritis; Psoriatic arthritis

Indexed keywords

ANTINUCLEAR ANTIBODY; C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; ETANERCEPT; GOLD; METHOTREXATE; PENICILLAMINE; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

AGED; CASE REPORT; CLINICAL EXAMINATION; DRUG WITHDRAWAL; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; KIDNEY BIOPSY; LUPUS ERYTHEMATOSUS NEPHRITIS; PERICARDITIS; PLEURISY; PROTEINURIA; PSORIATIC ARTHRITIS; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADRENAL CORTEX HORMONES; AGED; ANTIBODIES, ANTINUCLEAR; ARTHRITIS, PSORIATIC; BIOPSY; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY FUNCTION TESTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 35448960902     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-007-1104-6     Document Type: Review

References (19)

1. Klinkhoff A. Biological agents for rheumatoid arthritis: targeting both physical function and structural damage. Drugs 2004;64:1267-83.
2. Khanna D, McMahon M, Furst DE. Safety of tumor necrosis factor-alpha antagonists. Drug Saf 2004;27:307-24.
3. Maini R, St Clair EW, Breedveld F, et al. Infliximab versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9.
4. Shakoor N, Michalska M, Harris CA, et al. Drug induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002;359:579-80.
5. De Bandt M, Sibilia J, Le Loet X, et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 2005;7:R545-51.
6. Doulton TW, Tucker B, Reardon J, et al. Antineutrophil cytoplasmatic antibody associated necrotizing crescentic glomerulonephritis in a patient receiving treatment with etanercept for severe rheumatoid arthritis. Clin Nephrol 2004;62:234-8.
7. Den Broeder AA, Assmann KJ, van Riel PL, et al. Nephrotic syndrome as a complication of anti-TNFalpha in a patient with rheumatoid arthritis. Neth J Med 2003;61:137-41.
8. Kemp E, Nielsen H, Petersen LJ, et al. Newer immunmodulating drugs in rheumatoid arthritis may precipitate glomerulonephritis. Clin Nephrol 2001;55:87-8.
9. Stokes MB, Foster K, Markowitz GS, et al. Development of glomerulonephritis during anti-TNF-α therapy for rheumatoid arthritis. Nephrol Dial Transplant 2005;20:1400-6.
10. Charles PJ, Smeenk RJ, De Jong J, et al. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000;43:2883-90.
11. Jonsdottir T, Forslid J, van Vollenhoven A, et al. Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies. Ann Rheum Dis 2004;63:1075-8.
12. Aringer M, Graninger WB, Steiner G, et al. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 2004;50:3161-9.
13. Aringer M, Steiner G, Graninger WB, et al. Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus. Arthritis Rheum 2007;56:274-9.
14. Gordon C, Ranges GE, Greenspan JS, et al. Chronic therapy with recombinant tumor necrosis factor-alpha in autoimmune NZB/NZW F1 mice. Clin Immunol Immunopathol 1989;52:421-34.
15. Ofosu-Appiah W, Sfeir G, Viti D, et al. Suppression of systemic lupus erythematosus disease in mice by oral administration of kidney extract. J Autoimmun 1999;13:405-14.
16. Konoyannis D, Kollias G. Accelerated autoimmunity and lupus nephritis in NZB mice with an engineered heterozygous deficiency in tumor necrosis factor. Eur J Immunol 2000;30:2038-47.
17. Via CS, Shustov A, Rus V, et al. In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL. J Immunol 2001;167:6821-6.
18. Ferraccioli G, Mecchia F, Di Poi E, et al. Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections. Ann Rheum Dis 2002;61:358-61.
19. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.